Skip to main content
SpringerLink
Log in

PSA Biology and PC Screening

  • Chapter
Urological Cancer Management

  • 650 Accesses

Abstract

Prostate-specific antigen (PSA) is a serine protease of the tissue kallikrein family [1, 2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    EAU: European Association of Urology.

  2. 2.

    CCAFU: Comité de Cancérologie de l’Association Française d’Urologie.

  3. 3.

    AUA: American Urology Association.

References

  1. Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol. 2003;21(2):383–91.

    Article  CAS  PubMed  Google Scholar 

  2. Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev. 2001;22:184–204.

    CAS  PubMed  Google Scholar 

  3. Pretlow TG, Pretlow TP, Yang B, Kaetzel CS, Delmoro CM, Kamis SM, Bodner DR, Kursh E, Resnick MI, Bradley Jr EL. Tissue concentrations of prostate-specific antigen in prostatic carcinoma and benign prostatic hyperplasia. Int J Cancer. 1991;49(5):645–9.

    Article  CAS  PubMed  Google Scholar 

  4. Magklara A, Scorilas A, Stephan C, Kristiansen GO, Hauptmann S, Jung K, Diamandis EP. Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. Urology. 2000;56(3):527–32.

    Article  CAS  PubMed  Google Scholar 

  5. Diamandis EP, Yu H. Nonprostatic sources of prostate-specific antigen. Urol Clin North Am. 1997;24(2):275–82.

    Article  CAS  PubMed  Google Scholar 

  6. Howarth DJ, Aronson IB, Diamandis EP. Immunohistochemical localization of prostate-specific antigen in benign and malignant breast tissues. Br J Cancer. 1997;75(11):1646–51.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Tchetgen MB, Song JT, Strawderman M, Jacobsen SJ, Oesterling JE. Ejaculation increases the serum prostate-specific antigen concentration. Urology. 1996;47(4):511–6.

    Article  CAS  PubMed  Google Scholar 

  8. Herschman JD, Smith DS, Catalona WJ. Effect of ejaculation on serum total and free prostate-specific antigen concentrations. Urology. 1997;50(2):239–43.

    Article  CAS  PubMed  Google Scholar 

  9. Kravchick S, Bunkin I, Peled R, Yulish E, Ben-Dor D, Kravchenko Y, Cytron S. Patients with elevated serum PSA and indwelling catheter after acute urinary retention: prospective study of 63 patients with 7-year follow-up. J Endourol. 2007;21(10):1203–6.

    Article  PubMed  Google Scholar 

  10. Lin YH, Jiang YG, Li MC, Luo Y, Wang JS. Effects of prostate manipulation on serum total and free prostate specific antigen, and free-to-total prostate specific antigen ratio. Saudi Med J. 2010;31(9):999–1004.

    PubMed  Google Scholar 

  11. Kiran PR. Markedly raised serum prostate specific antigen levels. Prostatic infarction rather than malignancy? Aust Fam Physician. 2001;30(5):458–60.

    CAS  PubMed  Google Scholar 

  12. Mejak SL, Bayliss J, Hanks SD. Long distance bicycle riding causes prostate-specific antigen to increase in men aged 50 years and over. PLoS One. 2013;8(2):e56030. doi:10.1371/journal.pone.0056030.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Eastham JA, Riedel E, Scardino PT, Shike M, Fleisher M, Schatzkin A, Lanza E, Latkany L, Begg CB, Polyp Prevention Trial Study Group. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA. 2003;289(20):2695–700.

    Article  CAS  PubMed  Google Scholar 

  14. Moyer VA. Screening for prostate cancer: US Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2012;157:120–34.

    Article  PubMed  Google Scholar 

  15. Haute Autorité de Santé. Dépistage du cancer de la prostate chez les populations d’hommes présentant des facteurs de risque. Questions/Réponses 4 avril 2012. Available from www.has-sante.fr/portail/jcms/c_1238094/depistage- du- cancer- de- la- prostate- par- dosage- du- psa- interet- non- demontre- chez- les- hommes- presentant- des- facteurs- de- risque.

  16. Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, Holmberg L, Kantoff P, Konety BR, Murad MH, Penson DF, Zietman AL. Early detection of prostate cancer: AUA guideline. J Urol. 2013;190(2):419–26.

    Article  PubMed Central  PubMed  Google Scholar 

  17. Salomon L, Azria D, Bastide C, Beuzeboc P, Cormier L, Cornu F, et al. Comité de Cancérologie de l’AFU. Recommandations en onco- urologie : cancer de la prostate. Prog Urol Association française d’urologie. Cancer de la prostate et dépistage. 12/04/12; from www.urofrance.org/À leadmin/medias/afu/communiques/2012-03-15_cancer- prostate.pdf.

  18. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24(14):2137–50.

    Article  PubMed  Google Scholar 

  19. Schröder FH, Hugosson J, Roobol MJ, et al.; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009; 360:1320–8.

    Google Scholar 

  20. Vickers AJ, Ulmert D, Sjoberg DD, Bennette CJ, Björk T, Gerdtsson A, Manjer J, Nilsson PM, Dahlin A, Bjartell A, Scardino PT, Lilja H. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40–55 and long term risk of metastasis: case-control study. BMJ. 2013;346:f2023.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Heidenreich A, Abrahamsson PA, Artibani W, Catto J, Montorsi F, Van Poppel H, et al. Early detection of prostate cancer: European Association of Urology recommendation. Eur Urol. 2013;64:347–54.

    Article  PubMed  Google Scholar 

  22. Mottet N, Bastian PJ, Bellmunt J, et al. Guidelines on prostate cancer. The European Association of Urology. 2014, p. 17. Available from http://uroweb.org/wp-content/uploads/1607-Prostate-Cancer_LRV3.pdf#.

  23. Salomon L, Bastide C, Beuzeboc P, et al. Les members du CCAFU. Recommandations en Onco-Urologie 2013 du CCAFU: Cancer de la Prostate. Prog Urol. 2013;23(Suppl 2): S69–101. p. 6.

    Google Scholar 

  24. Salomon L, Azria D, Bastide C, Beuzeboc P, Cormier L, Cornu F, et al. Comité de Cancérologie de l’AFU. Recommandations en onco- urologie : cancer de la prostate. Prog Urol. 2010;20:S217–51.

    Article  PubMed  Google Scholar 

  25. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG, Southwick PC. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease, a prospective multicenter clinical trial. JAMA. 1998;279(19):1542–7.

    Article  CAS  PubMed  Google Scholar 

  26. Klotz LH. PSA recurrence: definitions, PSA kinetics, and identifying patients at risk. Can J Urol. 2006;13 Suppl 2:43–7.

    PubMed  Google Scholar 

  27. Llorente C, de la Morena JM, Ardura MA. PSA doubling time as a new diagnostic and prognostic method for prostate cancer. Arch Esp Urol. 2006;59(10):1083–7.

    Article  PubMed  Google Scholar 

  28. Arlen PM, Bianco F, Dahut WL, D’Amico A, Figg WD, Freedland SJ, Gulley JL, Kantoff PW, Kattan MW, Lee A, Regan MM, Sartor O, Prostate Specific Antigen Working Group. Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol. 2008;179(6):2181–5; discussion 2185–6.

    Article  PubMed Central  PubMed  Google Scholar 

  29. Crawford ED, Rove KO, Trabulsi EJ, Qian J, Drewnowska KP, Kaminetsky JC, et al. Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. J Urol. 2012;188:1726–31.

    Article  PubMed  Google Scholar 

  30. Sartori DA, Chan DW. Biomarkers in prostate cancer: what’s new? Curr Opin Oncol. 2014;26(3):259–64.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Shore N, Concepcion R, Saltzstein D, Lucia MS, van Breda A, Welbourn W, Lewine N, Gustavsen G, Pothier K, Brawer MK. Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer. Curr Med Res Opin. 2014;30(4):547–53.

    Article  PubMed  Google Scholar 

  32. Crawford ED, Scholz MC, Kar AJ, Fegan JE, Haregewoin A, Kaldate RR, Brawer MK. Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry. Curr Med Res Opin. 2014;30(6):1025–31.

    Article  PubMed  Google Scholar 

  33. Patel N, Vogel R, Chandra-Kuntal K, Glasgow W, Kelavkar U. A novel three serum phospholipid panel differentiates normal individuals from those with prostate cancer. PLoS One. 2014;6:9(3).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urology Department, The Royal Hospital, Muscat, Oman

    Said Abdallah Al-Mamari & Salim Said Al-Busaidy (Senior Consultant and HOD)

Authors
  1. Said Abdallah Al-Mamari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Salim Said Al-Busaidy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Said Abdallah Al-Mamari .

Editor information

Editors and Affiliations

  1. Urology Department, The Royal Hospital, Muscat, Oman

    Said Abdallah Al-Mamari

  2. Urology Department, The Royal Hospital, Muscat, Oman

    Salim Said Al-Busaidy

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Al-Mamari, S.A., Al-Busaidy, S.S. (2015). PSA Biology and PC Screening. In: Al-Mamari, S., Al-Busaidy, S. (eds) Urological Cancer Management. Springer, Cham. https://doi.org/10.1007/978-3-319-16301-7_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-16301-7_2

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-16300-0

  • Online ISBN: 978-3-319-16301-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation